Abstract
The burgeoning opportunities of the knowledge economy of biomedicine are matched by the governance challenges it poses to states in the pursuit of national advantage. The future markets are uncertain, the process of knowledge production from basic science to therapeutic product complex, and the possibility of failure ever present. Drawing on theories of the state, innovation and governance, this article explores the governance demands of knowledge production in biomedicine and the roles of state, regional levels of governance and private governance in the policy response. Applying the analytical framework derived from this discussion to the US case, the multi-dimensional governance of stem cell science in the arenas of science, society and the market is examined in an exploration of the USA's innovation capacity in this field.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
